Tedizolid
Oxazolidinone-class antibiotic / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Tedizolid?
Summarize this article for a 10 year old
Tedizolid, sold under the brand name Sivextro is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)).[5][medical citation needed]
Clinical data | |
---|---|
Trade names | Sivextro |
Other names | TR-700, torezolid[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614038 |
License data | |
Routes of administration | By mouth, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 91% |
Protein binding | 70–90% |
Elimination half-life | 12 hours |
Excretion | Feces |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.249.430 |
Chemical and physical data | |
Formula | C17H15FN6O3 |
Molar mass | 370.344 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
The most common side effects include nausea (feeling sick), headache, diarrhoea and vomiting.[4] These side effects were generally of mild or moderate severity.[4]
Tedizolid was approved for medical use in the United States in June 2014,[6][7] and for medical use in the European Union in March 2015.[4]